{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '3', 'Objectives(s), Hypothesis(es) and Enpoint(s)', '3.1 Primary Objective, Hypothesis, and Endpoint', '(1) Objective:', 'To compare the efficacy of active additive chemotherapy after definitive treatment', 'of metastases to structured follow-up.', 'Hypothesis:', 'Active additive chemotherapy after definitive treatment of metastases improves', 'progression-free survival.', 'Corresponding Endpoint:', 'PFS - Progression-free survival time defined as time from randomization to death', 'or evidence of disease relapse/progression (whatever occurs first)', '3.2 Secondary Objective(s), Hypothesis(es), and Endpoint(s)', '(1) Objective:', 'To compare efficacy of active treatment to structured follow-up by further efficacy', 'parameters and in different subgroups.', 'Hypothesis:', 'Subgroups, defined by various clinical parameters, display differences in efficacy', 'after active additive chemotherapy after definitive treatment of metastases.', 'Corresponding Endpoint(s):', 'PFS in', 'patients with/without prior systemic therapy;', 'in patients with R1 VS. R0 resected lesions;', 'patients with ablated VS. purely resected lesions.', 'os - Overall survival (OS) as time from randomization to the date of death of any', 'cause.', 'Number and type of treatments (including efficacy) beyond study participation.', 'Local or distant control of lesions according to ablative technique (surgery VS.', 'ablation vs. radiation)', '(2) Objective:', 'To compare safety of active treatment to structured follow-up only', 'Hypothesis:', 'Number of patients with SAEs is higher in the active treatment arm compared to the', 'structured follow-up, but comparable to fluoropyrimidine regimes in similar settings.', 'Corresponding Endpoint:', '(Serious) Adverse Events - Type, incidence, severity, and causal relationship to', 'active chemotherapy of non-serious adverse events and serious adverse events', '(severity evaluated according to CTCAE version 5.0)', 'Confidential', 'Page 26 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '(3) Objective:', 'To compare patient reported quality of life (QoL) of active treatment to structured', 'follow-up only.', 'Hypothesis:', 'QoL is moderately impacted by the active treatment for patients in Arm A, but', 'comparable to fluoropyrimidine regimes in similar adjuvant settings.', 'Corresponding Endpoint:', 'QoL - Quality of life (QoL) as assessed with the QoL questionnaire EQ-5D-5L.', '3.3 Exploratory Objective', '(1) Objective:', 'To identify and characterize patient subgroups with greatest benefit from treatment', 'including efficacy and toxicity using tumor specimen of primary and/or metastatic', 'tissue as well as blood samples at different time points for the identification of', 'biomarker candidates', 'Hypothesis:', 'Molecularly-defined subgroups display differences in efficacy and safety after active', 'additive chemotherapy after definitive treatment of metastases.', 'Corresponding Endpoint:', 'PFS, OS and Safety according to circulating tumor DNA at baseline (ctDNA positive', 'vs. negative).', 'PFS, os and Safety according to molecular subgroups.', 'Confidential', 'Page 27 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '4', 'Background and Rationale', '4.1 Colorectal Cancer Incidence', 'Colorectal cancer (CRC) is one of the most frequent malignancies in developed countries and', 'one of the leading causes of cancer-related deaths [Ferlay et al., 2007; Garcia et al., 2007;', 'Siegel et al., 2012]. Worldwide there are more than 1 million new cases diagnosed every year.', 'In Germany, colorectal cancer has a prevalence of 65-80/100.000, resulting in a total of', '~60.000 new cases every year. Up to 50% of patients develop metastases during the course', 'of their disease while 15-25% already present with synchronous metastases at first diagnosis', '[Howlader et al., 2011]. The current 5-year mortality is approximately 50% [Robert-Koch-', 'Institut, 2019].', 'In Western Europe, the burden of colorectal cancer is reported to be 211 (female) and 298', '(male) disability-adjusted life years (DALYs) on a population of 100.000 [Soerjomataram et al.,', '2012]. Given the available screening-programs in developed countries, no severe', 'socioeconomic impact within the incidence appears present. Life-style attitudes however may', 'affect individual risk.', '4.2 Treatment Options for Colorectal Cancer', 'When diagnosed before nodal involvement, treatment is usually limited to surgical resection.', 'Patients with nodal involvement are candidates for adjuvant chemotherapy with', 'fluoropyrimidines with or without oxaliplatin following initial surgery in the attempt to prevent', 'metastatic recurrence of the disease [Schmoll et al., 2012]. Once spread to distant sites,', 'treatment essentially consists of palliative chemotherapy.', '4.2.1 Fluoropyrimidine plus Oxaliplatin Regimes in Metastatic Colorectal Cancer', 'For most patients with metastatic colorectal cancer (mCRC) palliative chemotherapy regimens', 'with fluoropyrimidines and oxaliplatin and/or irinotecan remain the standard of care in first-and', 'second-line therapy [Van Cutsem et al., 2016].', 'A randomized phase III trial conducted by the Groupe Cooperateur Multidisciplinaire en', 'Oncologie (GERCOR) demonstrated a comparable efficacy in case of overall response rate', '(ORR), progression free survival (PFS) or overall survival (OS) between an irinotecan-based', '(FOLFIRI; irinotecan, leucovorin and 5-fluorouracil (5-FU)) or an oxaliplatin-based first line', 'chemotherapy (mFOLFOX-6; oxaliplatin, FA and 5-FU [Tournigand et al., 2004]).', 'However, differences were observed in case of side effects and toxicity with higher numbers', 'of patients suffering from grade 3 or 4 mucositis and nausea/vomiting treated with FOLFIRI', 'and higher numbers of patients developing grade 3 and 4 neutropenia and neurosensory', 'toxicity treated with mFOLFOX-6.', 'After failure of first line therapy, irinotecan- or oxaliplatin-based 5-FU-containing', 'chemotherapeutic regimes have also been shown to improve OS in second line therapy of', 'patients with mCRC [Andre et al., 1999a; Andre et al., 1999b; de Gramont et al., 1997;', 'Confidential', 'Page 28 of 79']\n\n###\n\n", "completion": "END"}